News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prestwick Pharmaceuticals, Inc. Release: Pivotal Phase III Data Of Tetrabenazine For The Treatment Of Chorea Associated With Huntington's Disease To Be Presented At American Neurological Association (ANA) Annual Meeting


10/19/2005 5:11:23 PM

Prestwick Pharmaceuticals, Inc., a CNS specialty pharmaceutical company, announced today that lead investigators from the Huntington Study Group will present results from a pivotal Phase III trial of tetrabenazine for the treatment of chorea associated with Huntington's Disease (HD) during a satellite symposium held in conjunction with the American Neurological Association 129th annual meeting in Toronto, Ontario, October 2-6.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES